Estimating long-run benefits of Immuno-oncology treatments: how early data cuts may exaggerate benefits
pharmaekonomi.substack.com
The typical CEA model of new cancer drugs extrapolates survival curves from clinical trial data. How much of the modeled long-term benefits depend on which data cutoff is used?
Estimating long-run benefits of Immuno-oncology treatments: how early data cuts may exaggerate benefits
Estimating long-run benefits of…
Estimating long-run benefits of Immuno-oncology treatments: how early data cuts may exaggerate benefits
The typical CEA model of new cancer drugs extrapolates survival curves from clinical trial data. How much of the modeled long-term benefits depend on which data cutoff is used?